• Publications
  • Influence
Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8α+ conventional dendritic cells
TLDR
Evidence is provided for a developmental relationship between lymphoid organ–resident CD8α+ cDCs and nonlymphoid CD103+ DCs and their shared developmental dependence on the transcription factor Irf8. Expand
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
TLDR
Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100). Expand
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
TLDR
In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. Expand
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
TLDR
The interleukin‐17 cytokine family plays a central role in psoriasis pathogenesis and is associated with atypical immune responses and central nervous system disorders. Expand
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.
TLDR
This review focuses on the emerging biology of the IL- 17 cytokine family in psoriasis, and on the molecular and genetic information gained from animal models and human clinical studies that confirm IL-17 as a crucial proinflammatory cytokine in psoriatic lesions. Expand
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
TLDR
Etanercept plus methotrexate combination therapy has not been adequately investigated in psoriasis and the safety and effectiveness of this combination therapy is still under investigation. Expand
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
TLDR
The primary end point was change in SARS-CoV-2 log viral load at day 11 (±4 days), and nine prespecified secondary outcome measures were evaluated with comparisons between each treatment group and placebo, and included 3 other measures of viral load, 5 on symptoms, and 1 measure of clinical outcome. Expand
Contrasting roles of the IL-1 and IL-18 receptors in MyD88-dependent contact hypersensitivity.
TLDR
Data indicate that the IL-1R and IL-18R/MyD88 pathways are required in distinctly different cells during the sensitization phase of CHS. Expand
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
TLDR
Bdalumab demonstrated sustained clinical response and an acceptable safety profile through 120 weeks in patients with moderate to severe psoriasis. Expand
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
TLDR
Etanercept is an effective, well-tolerated treatment for plaque psoriasis involving the scalp, and this study was insufficiently powered to detect rare adverse events potentially associated with etanercept. Expand
...
1
2
3
4
5
...